NCT06015230View on ClinicalTrials.gov

Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

March 8, 2022

Primary Completion Date

June 10, 2028

Study Completion Date

October 4, 2028

Conditions
Lupus Erythematosus, Systemic
Interventions
BIOLOGICAL

low dose GR1603 in phase Ⅰb

6 subjects in GR1603 low dose，2 subjects in placebo

BIOLOGICAL

high dose GR1603 in phaseⅠb

6 subjects in GR1603 high dose，2 subjects in placebo

BIOLOGICAL

low dose GR1603 in phase Ⅱ

low dose GR1603 monthly

BIOLOGICAL

high dose GR1603 in phase Ⅱ

high dose GR1603 monthly

BIOLOGICAL

Placebo in phase Ⅱ

Placebo

Trial Locations (1)

100730

Peking union Medical Hosipital, Beijing

All Listed Sponsors
lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY